SkyWater and NanoDx Partner to Develop and Produce Nanoscale Sensors for Rapid COVID-19 Testing and Other Vital Diagnostics

NanoDx product to be scaled and submitted for FDA Emergency Use Authorization

SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner and NanoDx, Inc., a privately held medical device company developing breakthrough, point-of-care diagnostic solutions, today announced technology transfer for qualification and production ramp of nanoscale sensors to enhance and expand accurate, rapid testing for several indications, including COVID-19, traumatic brain injury, sepsis and stroke. NanoDx is partnering with SkyWater to scale the product and plans to pursue an Emergency Use Authorization from the U.S. FDA for rapid, two-minute, point-of-care COVID-19 testing.

Read the article on WSJ.com: https://www.wsj.com/articles/skywater-and-nanodx-tm-partner-to-develop-and-produce-nanoscale-sensors-for-rapid-covid-19-testing-and-other-vital-diagnostics-01633525805?tesla=y

 

Return to Industry News Page